MAP La BAD et Inwi scellent un partenariat pour soutenir les start-up innovantes MAP Remise du prix Brahim Akhiat pour la diversité culturelle dans sa 2ème édition MAP M. El Malki se félicite du cheminement de la coopération avec le FOPREL MAP Une association marocaine lauréate du Prix Prince Mohamed Ben Fahd pour la meilleure action caritative MAP Le Maroc, pionnier dans la lutte contre la pandémie du coronavirus (Nabil Benabdallah) MAP Groupe de soutien à l’intégrité territoriale du Maroc à Genève: plein appui à la souveraineté du Royaume sur son Sahara MAP Marrakech : Immersion dans l’univers artistique d’Isabel Alonso Vega et Bence Magyarlaki MAP Covid-19: le HCR et la JICA mettent en place un projet de 275.000 dollars en faveur des réfugiés résidant au Maroc MAP L’artiste-plasticien Abderrahim El Hassani expose ses œuvres à Fès AGP Boké/société: Le siège de la préfecture, nouvelle cible des voleurs de motos

FDA/Cuba discuss production of COVID-19 vaccine

  12 Février      13        Santé (9429),


Accra, Feb. 12, GNA- Mrs Delese Darko, Chief Executive Officer, Food and Drugs Authority (FDA), has met with Mr Pedro Luis Despaigne Gonzalez, the Cuban Ambassador to Ghana, to discuss progress on the development of Cuba’s Covid-19 vaccine.

A statement issued by the FDA in Accra on Thursday, explained that the meeting followed an earlier one held in November 2020, where the Centre for State Control of Drugs and Medical Devices (CECMED) of the Ministry of Public Health of the Republic of Cuba (MINSAP), signed a Memorandum of Understanding with the FDA, to strengthen bilateral relations and cooperation in the area of health promotion.

It said the present meeting, which was at the request of the Ambassador, was therefore to brief Ghana’s FDA on the status of clinical trials being conducted in Cuba on four Covid-19 candidate vaccines, with each at different phases of clinical development.

According to Mr Gonzalez, the COVID-19 vaccine, “Soberana 02”, was Cuba’s most advanced candidate against the COVID-19 virus, which had currently passed Phase I trials in Cuba.

He indicated that Phase II trials had also been carried out on 910 patients, while Phase III trials would commence in February 2021.

Mr Gonzalez again said Cuba intended to offer the transfer of technology through an agreement with the Ghanaian Pharmaceutical Industry for the supply of the active pharmaceutical ingredients for the formulation, production and packaging of the vaccine in Ghana.

According to the statement, Mr Gonzalez had stated that countries like India, Vietnam, Iran, Venezuela and Pakistan had also expressed interest in acquiring the Soberana 02 vaccine.

Mrs. Darko on her part had expressed gratitude to the people and Government of Cuba for their continued solidarity, and pledged the continued support of the FDA in the sharing of its experience as a Maturity Level three regulatory agency of the World Health Organization (WHO).

She further expressed her utmost appreciation for the intended technological transfer support from Cuba, stressing that the meeting presented an opportunity to render support, build capacity, further develop and challenge the local pharmaceutical industry (allopathic and herbal).

She said through the relationship, the pharmaceutical industry would make advances in promoting health, thus improving the health standards of the Ghanaian.

Present at the meeting were Mr. Seth Seneake, the Deputy Chief Executive Officer for Health Products and Technologies Division, Mrs Yvonne Nkrumah, the Deputy CEO for Corporate Services, and Mrs Mercy Mintah Gyampoh, the Pharmaceutical liaison for the Republic of Cuba in Ghana.

Dans la même catégorie